Lung cancer is one of the leading causes of cancer-related death worldwide, and there is an urgent need to develop more reliable preclinical models to identify effective treatments. Moreover, lung cancer exhibits significant heterogeneity between individuals and requires precision medicine to achieve comprehensive management. Lung cancer organoids (LCOs) are derived from patients' tumor tissues or tumor cells, which enables them to faithfully recapitulate in vivo tumor characteristics and heterogeneity, providing a promising platform to study drug resistance mechanisms and predict therapy efficacy. Here, we described the construction of LCOs and their application in precision therapy. We also discussed the limitations and prospects of current organoids research.
肺癌是全球癌症相关死亡的主要原因之一，迫切需要开发更可靠的临床前模型以便确定有效的治疗方法。并且，肺癌在个体间显示出显著的异质性，需要精准治疗来实现全程管理。肺癌类器官直接来源于患者肿瘤组织或细胞，保留了肿瘤原始的组织结构和分子特征，有望成为研究耐药机制和预测患者疗效的良好模型。本文详细阐述了患者来源肺癌类器官的构建方法和精准治疗中的应用，并讨论了目前类器官研究的局限性和未来的前景。.